Sudarshan Pharma Industries Ltd — Important, 31-01-2026: Company Update

Sudarshan Pharma Industries has released an investor presentation detailing its strategic roadmap and recent achievements. Key highlights include the proposed fund-raising of USD 35 Million via FCCB and the acquisition of a manufacturing unit at Rs. 25.50 Crore from Srigen Lifesciences to enhance bulk drug and intermediate production. The company also noted its BSE SME listing in March 2023 and strategic acquisitions like Ratna Lifesciences. Financially, for the fiscal year 2025, the company achieved a Revenue from Operations of 505.0 Cr, Operating EBITDA of 39.9 Cr, and Profit After Tax of 16.0 Cr, demonstrating robust growth and an expansion into new markets.